Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment.

Fessel WJ, Anderson B, Follansbee SE, Winters MA, Lewis ST, Weinheimer SP, Petropoulos CJ, Shafer RW.

Antiviral Res. 2011 Dec;92(3):484-7. doi: 10.1016/j.antiviral.2011.09.010. Epub 2011 Oct 4.

2.

Increased rates of appendicitis in HIV-infected men: 1991-2005.

Klein DB, Hurley LB, Horberg MA, Silverberg MJ, Follansbee SE, Flamm JA, Green GM.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):139-40. doi: 10.1097/QAI.0b013e3181b05d52. No abstract available.

PMID:
19704266
3.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.

4.

Maraviroc for previously treated patients with R5 HIV-1 infection.

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.

5.

The state of the science of HIV treatment approaches.

Follansbee SE.

Focus. 2007 Jan;22(1):1-5. No abstract available.

PMID:
17526105
6.

Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.

Horberg MA, Hurley LB, Klein DB, Follansbee SE, Quesenberry C, Flamm JA, Green GM, Luu T.

Arch Surg. 2006 Dec;141(12):1238-45.

PMID:
17178967
8.

Salvage therapy and formulation of highly active antiretroviral therapy.

Fessel WJ, Follansbee SE, Young TP.

J Acquir Immune Defic Syndr. 2000 Jun 1;24(2):194-5. No abstract available.

PMID:
10935698
9.

Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.

Chou S, Marousek G, Guentzel S, Follansbee SE, Poscher ME, Lalezari JP, Miner RC, Drew WL.

J Infect Dis. 1997 Sep;176(3):786-9.

PMID:
9291334
10.
11.

The dying process.

Follansbee SE.

Focus. 1996 Jan;11(2):5-6.

PMID:
11363151
12.

Oral ganciclovir for cytomegalovirus infections.

Follansbee SE, Stempien MJ, Buhles WC.

Adv Exp Med Biol. 1996;394:93-103. Review. No abstract available.

PMID:
8815713
13.

Activation of virus replication after vaccination of HIV-1-infected individuals.

Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, Feinberg MB.

J Exp Med. 1995 Dec 1;182(6):1727-37.

14.

Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group.

Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, Benson CA, Friedberg DN, Hubbard L, Stempien MJ, et al.

N Engl J Med. 1995 Sep 7;333(10):615-20.

15.

Prosthetic joint infection due to Mycobacterium tuberculosis: report of three cases.

Tokumoto JI, Follansbee SE, Jacobs RA.

Clin Infect Dis. 1995 Jul;21(1):134-6. Review.

PMID:
7578722
16.

Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group.

Dohn MN, Weinberg WG, Torres RA, Follansbee SE, Caldwell PT, Scott JD, Gathe JC Jr, Haghighat DP, Sampson JH, Spotkov J, Deresinski SC, Meyer RD, Lancaster DJ.

Ann Intern Med. 1994 Aug 1;121(3):174-80.

PMID:
7880228
17.

Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS.

Kemper CA, Hostetler JS, Follansbee SE, Ruane P, Covington D, Leong SS, Deresinski SC, Stevens DA.

Clin Infect Dis. 1993 Sep;17(3):344-52. Review.

PMID:
8218674
18.

Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.

Fischl MA, Olson RM, Follansbee SE, Lalezari JP, Henry DH, Frame PT, Remick SC, Salgo MP, Lin AH, Nauss-Karol C, Lieberman J, Soo W.

Ann Intern Med. 1993 May 15;118(10):762-9.

PMID:
8097082
19.

A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group.

Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, Graybill JR, Sugar AM, McAuliffe VJ, Follansbee SE, et al.

N Engl J Med. 1992 Mar 19;326(12):793-8.

20.

Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection.

Drew WL, Miner RC, Busch DF, Follansbee SE, Gullett J, Mehalko SG, Gordon SM, Owen WF Jr, Matthews TR, Buhles WC, et al.

J Infect Dis. 1991 Apr;163(4):716-9.

PMID:
1849157

Supplemental Content

Loading ...
Support Center